soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Michael Albert, MD on X: "🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Cardiovascular Outcomes, Safety, and Tolerability

The resulting increase in GABA release helps restore the balance of excitatory and inhibitory neurotransmission by decreasing glutamate activity, promoting neuronal survival, and enhancing mitochondrial function

14 years of research and development, a total of 19 Chinese invention patents and 2 international invention patents have been declared, of which 7 Chinese invention patents and 8 software copyrights have been authorized

Even more impressive, about 86% of participants had a weight reduction of 5% or more from their baseline body weight by the end of the study

"FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize"